Wu W, Wang HD, Guo W, Yang K, Zhao YP, Jiang YG, He P. Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2010;
29:49. [PMID:
20470393 PMCID:
PMC2877011 DOI:
10.1186/1756-9966-29-49]
[Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/27/2010] [Accepted: 05/14/2010] [Indexed: 11/22/2022]
Abstract
Background/Aim
Fas/FasL system is a major regulator of apoptosis. The mechanisms by which Fas mediates cisplatin resistance remain unclear. The aim of this study is to explore the effect of Fas over-expression on cisplatin resistance of small cell lung cancer cells and its possible mechanisms.
Materials and methods
Fas was over-expressed in H446/CDDP cells by infection with the adenoviruses containing Fas. Sensitivity of Fas-overexpressed H446/CDDP cells to cisplatin was evaluated using MTT assay. Expressions of Fas, GST-π and ERCC1 were detected by RT-PCR and Western blot analysis. Apoptosis rate was examined by FACS.
Results
Over-expression of Fas in H446/CDDP cells significantly decreased the expressions of GST-π and ERCC1 at mRNA and protein levels, and increased the cell apoptosis. Furthermore, up-regulation of Fas significantly decreased the tolerance of H446/CDDP cells to cisplatin.
Conclusion
Over-expression of Fas reverses drug resistance of H446/CDDP cells, possibly due to the increased cell sensitivity to apoptosis and the decreased expressions of GST-π and ERCC1.
Collapse